Results 181 to 190 of about 12,750 (303)

Recombinant Monoclonal Antibodies for Detecting the Tubulin Post‐Translational Modifications Glutamylation and Lysine‐40 Acetylation

Cytoskeleton, EarlyView.
ABSTRACT Post‐translational modifications (PTMs) to tubulin subunits in microtubule filaments are thought to comprise a component of the tubulin code that specifies microtubule functions in cell physiology and animal development. Acetylation of Lysine‐40 (K40) on α‐tubulin (αTub‐K40ac) and glutamylation of both α‐ and β‐tubulin are two tubulin PTMs of ...
Lynne Blasius, Ezekiel C. Thomas, Erik H. Collet, Erin Jenson, Chad G. Pearson, Ryoma Ohi, Kristen J. Verhey   +6 more
wiley   +1 more source

IntegriLAB: a blockchain-enabled electronic lab notebook for reproducible neuroimaging research. [PDF]

Front Neuroinform
Easmin R, Veronese M, Allen P, Nordio G, Turkheimer F.   +4 more
europepmc   +1 more source

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Clinical Pharmacology &Therapeutics, EarlyView.
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, Beata Holkova, Girish S. Gudi, Adam Drake, Maria Pihlgren, Piet H. van der Graaf, Sunitha GN, Andrew Garton, Mario Perro, Cyril Konto, Lida Pacaud   +11 more
wiley   +1 more source

Blockchain Smart Contracts for Automating Clinical Trials: Systematic Review and Proposed System Architecture. [PDF]

JMIR Med Inform
Sheikh Z, Samarth G, Jaffer U.
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

The Design and Development of a Novel Device that Converts a Patient-Controlled Intravenous Pump into an Oral Liquid Medication Dispenser for Non-Controlled Substances. [PDF]

Med Devices (Auckl)
El-Khalili T, Varma L, Yung KY, Li J, Wiznia D.   +4 more
europepmc   +1 more source

Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug‐Resistant Tuberculosis

Clinical Pharmacology &Therapeutics, EarlyView.
Pretomanid is a component of the World Health Organization‐recommended treatment regimen for drug‐resistant tuberculosis in patients aged ≥ 14 years. While preclinical rodent studies identified testicular toxicity as a potential clinical liability at elevated doses, no corresponding effects were observed in nonhuman primates nor clinical hormone ...
Pauline Howell, Antonio Lombardi, William Brumskine, Lali Mikiashvili, Kim Boekelheide, Joanna Moreira, Alda Holsta, Matthew Betteridge, Lindsay Thompson, Angela Crook, Paul Bruinenberg, Maria Beumont, Eugene Sun, Francesca Conradie   +13 more
wiley   +1 more source

Integrating AI-blockchain framework with Spider Monkey Federated Extreme Learning for enhanced healthcare data protection. [PDF]

Sci Rep
Nishok VS, Dhanasekaran S, Suresh G, Anandaraj APS.   +3 more
europepmc   +1 more source

Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma

Clinical Pharmacology &Therapeutics, EarlyView.
The minimal anticipated biological effect level (MABEL) approach to first‐in‐human (FIH) dose calculation can lead to long dose‐escalation periods before observing clinical activity. We used a novel ex vivo MABEL approach to calculate the FIH starting dose for forimtamig, a T‐cell bispecific antibody under investigation for the treatment of relapsed ...
Thomas E. Kraft, Estelle Marrer‐Berger, Sara Belli, Helene Haegel, Anneliese Schneider, Anna Maria Giusti, Michael Bscheider, Wolfgang Jacob, Martin Weisser, Laura Blanco, Nicolas Frances, Eva Rossmann, Guido Steiner, Aintzane Zabaleta Azpiroz, Bruno Paiva, Ludovic Martinet, Tanja Fauti   +16 more
wiley   +1 more source

VeriFed: Temporally Consistent Continuous Cross-Chain Data Federation. [PDF]

Entropy (Basel)
Hao K, Bi M, Ma Y.
europepmc   +1 more source